Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | PLA2G2A | P14555 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | ADAM17 | P78536 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 2/20 | 0.43 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.43 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.43 |
| ▸ | CNR2 | P34972 | 1/20 | 0.42 |
| ▸ | ABCC2 | Q92887 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3849564 | 0.89 | CHRNB2 (0.53) | MAPTPLA2G2AKMT2APOLBADAM17 | |
| SCHEMBL3853681 | 0.88 | MAPT (0.52) | MAPTPLA2G2AKMT2APOLBADAM17 | |
| SCHEMBL3849173 | 0.88 | MAPT (0.55) | MAPTPLA2G2AKMT2APOLBADAM17 | |
| SCHEMBL3853673 | 0.83 | KMT2A (0.51) | MAPTKMT2APOLBADAM17ALDH1A1 | |
| SCHEMBL3849200 | 0.82 | TP53 (0.48) | MAPTKMT2APOLBALDH1A1TP53 | |
| SCHEMBL3851327 | 0.82 | KMT2A (0.52) | MAPTKMT2AADAM17ALDH1A1LMNA | |
| SCHEMBL3855721 | 0.81 | ALDH1A1 (0.50) | MAPTKMT2APOLBADAM17ALDH1A1 | |
| SCHEMBL3848327 | 0.81 | ADAM17 (0.56) | MAPTPLA2G2AKMT2APOLBADAM17 | |
| SCHEMBL3848336 | 0.81 | ADAM17 (0.56) | MAPTPLA2G2AKMT2APOLBADAM17 | |
| SCHEMBL3854563 | 0.78 | KMT2A (0.52) | MAPTPLA2G2AKMT2AALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7576222-B2 | N-{[4-(but-2-ynyloxy)phenyl]sulfonyl}-1-(2-fluorobenzyl)-5-methoxy-2-methyltryptophan; for treatment of rheumatoid arthritis, juvenile rheumatoid arthritis, ulcerative colitis, or Crohn's disease | WYETH (US) | 2009-08-18 | — | — | US | disclosed |
| US-20060160884-A1 | Alkynyl-containing tryptophan derivative inhibitors of tace/matrix metalloproteinase | WYETH (US) | 2006-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060160884-A1 | Alkynyl-containing tryptophan derivative inhibitors of tace/matrix metalloproteinase | ADAM17, TPSAB1, ADAM10 | MAPT 1572/4885PLA2G2A 3197/4885KMT2A 1950/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.